8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

November 15, 2013

Date of Report (Date of earliest event reported)

IMMUNOTECH LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Nevada	333-57514	95-4834274
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification Number)

120 W. Pomona Ave. Monrovia, California	91016
(Address of principal executive offices)	(Zip Code)

(818) 409-9091

Registrant’s telephone number, including area code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[  ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.06                    Shell Company Status 

The Company is NOT a a reporting “shell company, as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended. It is the determination of management and counsel Immunotech Laboratories Inc. F/K/A International Technology Systems Inc. F/K/A International Telecommuication, Inc. F/K/A EarthNetMedia Inc. has not nor has ever been a “shell” company.

Item 9.01                    Financial Statements and Exhibits

 
d) Exhibit. See Attached

Exhibit

Number               Description

99.1                      Press Release

SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		IMMUNOTECH LABORATORIES, INC.
Date: November 15, 2013	By:	/s/ Harry Zhabilov
		Harry Zhabilov
		President

EX-99.1

info@immunotechlab.com

Source: Immunotech Laboratories, Inc. ( IMMB )

Immunotech Laboratories, Inc.

Monrovia, Calif.---- 11/15, 2013--- Immunotech Laboratories, Inc.

(Please see accompanying document in PDF format.)

Further information can be obtained from www.immunotechlab.com

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.